Macleod Colin
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- Neurology top 5%
- Long-Term Effects of COVID-19
Papers in
-
- SARS-CoV-2 and COVID-19 Research 2
-
- Emergency and Acute Care Studies 1
- Journals
- The Lancet (5 papers)EClinicalMedicine (1 paper)Journal Européen des Urgences (1 paper)
- Partner nations
- United KingdomAustraliaIndonesia
In The Last Decade
Macleod Colin
7 papers receiving 1.1k citations
Macleod Colin's Hit Papers
Peers
Comparison fields: 5 of 89
- Infectious Diseases 729
- Neurology 251
- Internal Medicine 54
- Obstetrics and Gynecology 69
- Critical Care and Intensive Care Medicine 34
Countries citing papers authored by Macleod Colin
This map shows the geographic impact of Macleod Colin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Macleod Colin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Macleod Colin more than expected).
Fields of papers citing papers by Macleod Colin
This network shows the impact of papers produced by Macleod Colin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Macleod Colin. The network helps show where Macleod Colin may publish in the future.
Co-authors
The 2 scholars most cited alongside Macleod Colin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 4 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 5 | 2023 | 83 | |
| 6 | 2025 | 2 | |
| 7 | 2007 | 1 |
About Macleod Colin
Macleod Colin is a scholar working on Infectious Diseases, Emergency Medicine, General Health Professions, Insect Science and Renewable Energy, Sustainability and the Environment, having authored 7 papers that have together received 1.2k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers), Emergency and Acute Care Studies (1 paper), Healthcare Systems and Practices (1 paper) and Health, Medicine and Society (1 paper). The work is most often cited by research in Infectious Diseases (729 citations), Neurology (251 citations), Internal Medicine (54 citations), Obstetrics and Gynecology (69 citations) and Critical Care and Intensive Care Medicine (34 citations). Macleod Colin has collaborated with scholars based in United Kingdom, Australia and Indonesia. Frequent co-authors include Hélène Bouvaist and J.‐L. Moreau. Their work appears in journals such as The Lancet, EClinicalMedicine and Journal Européen des Urgences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.